Simeprevir with Peginterferon and Ribavirin in GT-4
RESTORE

Simeprevir + Peginterferon + Ribavirin in Genotype 4
RESTORE: Study Features

RESTORE Trial: Features

- **Design**: Open-label, phase 3, study evaluating simeprevir + PEG + RBV for treatment naïve and experienced patients with genotype 4 chronic HCV

- **Setting**: Multicenter and International

- **Entry Criteria**
  - Chronic HCV genotype 4 (n = 107)
  - Treatment naïve (n = 35) or treatment experienced relapsers (n = 22)
  - Experienced (Nonresponder): partial (n = 10), null (n = 40)

- **Patient Characteristics**
  - Sex: male 79%
  - Race: white (72%); black (28%)
  - Median age: 49
  - IL genotype: 7.5% CC
  - METAVIR Fibrosis Stage: F4 = 29%; F3 = 14%

- **Primary End-Points**: Efficacy (SVR12)

# Simeprevir + Peginterferon + Ribavirin in Genotype 4
## RESTORE: Study Design

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>12</th>
<th>24</th>
<th>48</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Treatment-Naïve or Prior Relapse

- **RGT** determines if PEG + RBV x 24 or 48 wks

### Partial Response or Null Response

- **RGT** criteria: Week 4 HCV RNA < 25 IU/mL (detectable or undetectable) and Week 12 HCV RNA < 25 IU/mL (undetectable)

### Drug Dosing

- **Simeprevir**: 150 mg once daily
- **Peginterferon alfa-2a (PEG)**: 180 mcg/week
- **Ribavirin (RBV)** weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg

---

**Source**: Moreno C, et al. 49th EASL. April 2014: Abstract P1319.
Simeprevir + Peginterferon + Ribavirin in Genotype 4
RESTORE: Results

RESTORE: SVR12 by Prior Treatment Status

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online  
www.hepatitisc.uw.edu

Hepatitis Web Study  
http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.